Previous 10 | Next 10 |
Adamas Pharma (NASDAQ: ADMS ): Q1 GAAP EPS of -$0.59 beats by $0.23 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS),...
EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a confere...
Stocks market indices have gained a large portion of their value back after having been down as much as 34% over the past month. The major market averages are now off their high less than 20%. The unpredictable massive rally in these benchmarks included record moves that will surely be studied i...
Adamas Pharmaceuticals, Inc. (ADMS) Q4 2019 Results Earnings Conference Call February 25, 2020, 04:30 PM ET Company Participants Peter Vozzo - Investor Relations, Westwicke Partners Neil McFarlane - CEO & Director Christopher Prentiss - Chief Financial Officer Vijay Shreedh...
Adamas Pharma (NASDAQ: ADMS ): Q4 GAAP EPS of -$0.83 misses by $0.02 . Revenue of $16.35M (+22.7% Y/Y) beats by $0.09M . Shares +1.7% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
- Full year 2019 GOCOVRI ® product sales of $54.6 million, a 60% increase over 2018; total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI ® product sales of $16.3 million, a 23% increase over fourth quarter 2018; total paid prescriptions...
EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the...
EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas’ management team will host a co...
EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVR...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...